# 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

> **NCT05547386** · PHASE3 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 163 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** Gallium Ga 68 Gozetotide
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05547386
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05547386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05547386, "68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05547386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*